Company news
Anaptysbio, Inc. (NASDAQ:ANAB) news
Anaptysbio, Inc. news releases on 6ix. Latest, Jan 7, 2021: AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Press releases — page 3
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 6, 2021
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
November 12, 2020
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
November 3, 2020
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
October 25, 2020
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
October 12, 2020
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
September 10, 2020
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
August 9, 2020
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
August 9, 2020
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
August 4, 2020
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
July 30, 2020
AnaptysBio Expands Executive Leadership Team
July 14, 2020
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
July 7, 2020
AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
May 5, 2020
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
March 1, 2020
AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
February 24, 2020
AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
January 7, 2020
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
November 7, 2019
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
November 7, 2019
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
September 29, 2019
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
September 26, 2019